TB-500 is a seven-amino-acid fragment of thymosin beta-4. A plain-language tour of every research area the published record actually covers, and what it does not.
The human skin-wound trials often linked to TB-500 tested thymosin beta-4, the larger parent protein. Here is what those studies reported, and what they did not.
TB-500 is a seven-amino-acid fragment of thymosin beta-4, a 43-amino-acid protein about five times heavier. Here is what the published research actually tested.
TB-500 is a 7-amino-acid fragment of thymosin beta-4. Here is what repair research actually tested, which form it used, and what has never been studied in people.
What published research reports about TB-500 and thymosin beta-4 safety, including the one human safety study, the negative findings, and the gaps nobody has filled.
A randomized human trial of thymosin beta-4 after a heart attack was null overall, with a signal only in an early-dosing subgroup. Both halves explained.
Two published studies found thymosin beta 4 weakened the gut lining in rats and mice. Here is what they measured, what they did not test, and why we publish it.
The eye is where thymosin beta-4 has the most human data. A plain-language look at the dry eye trials, the p=0.0656 Phase III, and what is still missing.
The published thymosin beta-4 study figures, the animal numbers, and the honest answer for TB-500 itself: no human dose has ever been published.
One published animal study gave TB-500 itself and measured brain outcomes. Here is what it reported, the result it did not find, and what is still missing.